Press coverage about Aralez Pharmaceuticals (NASDAQ:ARLZ) has been trending somewhat negative recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a news impact score of -0.03 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.3364258018754 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of analysts have recently issued reports on ARLZ shares. Chardan Capital dropped their price target on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating on the stock in a report on Thursday, August 10th. ValuEngine downgraded shares of Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) traded up 0.88% during mid-day trading on Friday, hitting $1.14. 459,080 shares of the stock were exchanged. The stock’s 50 day moving average is $1.28 and its 200-day moving average is $2.03. Aralez Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $6.80. The stock’s market cap is $76.21 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.01. Aralez Pharmaceuticals had a negative net margin of 122.35% and a negative return on equity of 90.17%. The company had revenue of $27.62 million for the quarter, compared to analyst estimates of $21.37 million. During the same quarter last year, the company earned ($0.27) EPS. The business’s revenue was up 119.6% compared to the same quarter last year. On average, analysts anticipate that Aralez Pharmaceuticals will post ($1.62) EPS for the current year.

In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch purchased 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were bought at an average price of $1.17 per share, for a total transaction of $58,500.00. Following the acquisition, the director now owns 206,609 shares in the company, valued at $241,732.53. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew I. Koven sold 161,906 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $1.28, for a total transaction of $207,239.68. Following the completion of the transaction, the insider now owns 1,363,695 shares in the company, valued at approximately $1,745,529.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 569,115 shares of company stock worth $790,719. Corporate insiders own 6.70% of the company’s stock.

WARNING: “Aralez Pharmaceuticals (ARLZ) Receiving Somewhat Negative News Coverage, Report Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.